What changed recently

AUA amended the 2022 guideline after a literature review covering July 2021 to December 2024 (29 studies plus a set on artificial intelligence in disease management). The society describes the amendment as refining risk-based management, updating imaging and radiation therapy guidance, and strengthening the shared decision-making statements.

ESMO replaced its 2023 metastatic colorectal cancer guideline with the 2026 edition (Cremolini et al., Ann Oncol 37(6):759-776); the 2023 document is now marked superseded in this atlas.

The EAU panel describes the 2026 text as a limited update of the 2025 publication, with revised evidence summaries and recommendations for MRI in biopsy indication and strategy, for staging, and for active surveillance strategy, plus an adapted EAU risk-group table for localised and locally advanced disease.

This living-guideline version bump revisits the evidence base from a February 2026 literature search and issues updated recommendations covering the teclistamab plus daratumumab combination; the preceding 2026.1.0 release had itself replaced the 2019 guideline by adding first-ever guidance on smoldering myeloma and incorporating CAR T-cell, bispecific antibody and antibody-drug conjugate options.

The 2025 ASH panel retired the 2020 guideline's split between "intensive" and "non-intensive" therapy, framing recommendations instead around candidacy for antileukaemic therapy, and it now positions venetoclax-based combinations alongside conventional induction and post-remission therapy for older adults with newly diagnosed AML.

NCCN's published Insights article for this version bump describes the panel's discussion of newly incorporated data in three areas: CD3xCD20 bispecific antibodies and CD19-directed antibodies/antibody-drug conjugates in relapsed or refractory follicular lymphoma, BTK inhibitor-based regimens in TP53-mutated classical mantle cell lymphoma, and bispecific antibodies added to chemoimmunotherapy in relapsed or refractory DLBCL.

The EHA-EMN 2025 guideline replaced the 2021 EHA-ESMO guideline, adopting the R2-ISS staging system and adding minimal residual disease, circulating plasma cells and mass-spectrometry monoclonal protein as prognostic factors, alongside 14 novel EMA/FDA-approved regimens.

ESMO states this edition supersedes the 2019 early breast cancer guideline. It gives gene expression assays and endocrine response assessment a formal role in deciding whether adjuvant chemotherapy is needed when clinicopathological factors are equivocal, and it restricts baseline imaging for distant metastases to stage IIB or higher, high-recurrence-risk or symptomatic patients rather than routine staging.

The 2022 ELN revision reworked genetic risk stratification: the FLT3-ITD allelic ratio was dropped as a classifier and FLT3-ITD without NPM1 mutation moved out of the adverse group, in-frame bZIP CEBPA mutations were accepted as favourable whether mono- or biallelic, and myelodysplasia-related gene mutations were added as adverse regardless of any prior MDS history.

This revision of the 2011 BSG guideline moved oral iron replacement to a lower, once-daily (or alternate-day) dosing schedule rather than the older two-to-three-times-daily regimens, and reworked the diagnostic pathway for who needs bidirectional endoscopy and coeliac serology in confirmed iron deficiency anaemia.

The 2021 update revised the 2018 focused update mainly on the strength of the KATHERINE trial, adding adjuvant ado-trastuzumab emtansine for HER2-positive patients left with residual invasive disease after neoadjuvant chemotherapy plus HER2-directed therapy instead of continuing trastuzumab. A 2024 rapid recommendation update subsequently folded in adjuvant CDK4/6 inhibitors for high-risk hormone receptor-positive disease.

This report updates the 2010 International Consensus Report, regrading evidence published 2009-2018 and incorporating the newer agents (notably thrombopoietin receptor agonists) into the adult, paediatric and pregnancy treatment pathways, alongside new sections on quality of life.

The 2019 ASH update replaced the 2011 guideline: corticosteroids (prednisone or dexamethasone) became the preferred first-line drug therapy in children over IVIg or anti-D, observation was favoured for children with no or mild bleeding, and thrombopoietin receptor agonists moved earlier in the second-line sequence ahead of rituximab and splenectomy.

The 2019 ESC/ERS update replaced the 2014 guideline, making direct oral anticoagulants the preferred agents for acute and long-term treatment of most pulmonary embolism patients, tightening the diagnostic algorithm around clinical probability and D-dimer (including a dedicated pathway for pregnancy), and adding structured follow-up for post-PE symptoms and chronic thromboembolic disease.